Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of 113 healthcare workers in Catalonia who were followed during three years. The ...

Zenas BioPharma, Inc.'s obexelimab's potential in treating autoimmune diseases and upcoming phase 2 & 3 trial results. Read ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

The U.S. Food and Drug Administration has granted regenerative medicine advanced therapy (RMAT) designation to Fate's FT819 ...

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...

The following is a summary of “Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab,” published in the April 2025 issue of Journal of ...

The latest biotech to roll out of Third Rock Ventures is working on Fc-based therapeutics it hopes could offer new treatment ...

These therapeutics are designed to eliminate only the pathogenic antibodies while sparing healthy immune components. This novel approach also targets the B cells that produce the pathogenic ...

The Lupus Research Alliance (LRA) is proud to announce the recipients of this year’s Lupus Innovation Award (LIA), addressing many critical themes in lupus research including novel therapeutic ...

a key factor in B-cell-mediated diseases. The antibody's mechanism of action includes blocking APRIL's binding to its receptors and promoting its degradation. The new bind-and-release design of ...

Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...